Milrinone Versus Placebo in Patients With Septic Shock

Summary

Sepsis is one of the most serious healthcare problems, worldwide, and financial burdens. The overall mortality of severe sepsis/septic shock was 44.5-52.6%. A common cause of death is refractory shock and multi-organ failure. Myocardial dysfunction is a relatively common complication of septic shock. This causes a decrease in the amount of cardiac output, resulting in insufficient blood supply to the organ and multi-organ failure and lead to death Early goal-directed therapy began to use dobutamine in patients with septic shock Sepsis Survival Campaign Guideline 2016 recommended drug is dobutamine and an alternative drug is milrinone in septic shock patients with clinical signs of poor tissue perfusion.

Timeline

Start

2021-12-01

Primary completion

2024-12

Completion

2025-06

Outcome

Met primary endpoint

paper The milrinone group demonstrated a significantly greater change in cardiac output at 6 h (median [IQR] 0.62 L/min [-0.51 to 1.47]) than did the placebo group PMID 40138463 ↗

Publications

• Tongyoo S, Chobngam S, Yolsiriwat N, Jiranakorn C. Effects of adjunctive milrinone versus placebo on hemodynamics in patients with septic shock: a randomized controlled trial. Ann Med. 2025 Dec;57(1):2484464. doi: 10.1080/07853890.2025.2484464. Epub 2025 Mar 26.

Drugs

Indications